Screener
Xenon Pharmaceuticals XENE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Xenon Pharmaceuticals’s reported figures.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's EBITDA?
- Xenon Pharmaceuticals (XENE) reported EBITDA of -$122.6M in Q2 2026.
- How has Xenon Pharmaceuticals's EBITDA changed year-over-year?
- Xenon Pharmaceuticals's EBITDA decreased by 31.0% year-over-year, from -$93.6M to -$122.6M.
- What is the long-term trend for Xenon Pharmaceuticals's EBITDA?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's EBITDA has grown at a 68.0% compound annual growth rate (CAGR), from -$78.09M to -$370.53M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Xenon Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude